Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD
12.80 -1.15 (-8.24%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap595.28M
Revenue (ttm)n/a
Net Income (ttm)-70.17M
Shares Out46.51M
EPS (ttm)-5.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume242,145
Open13.65
Previous Close13.95
Day's Range12.65 - 14.01
52-Week Range12.65 - 45.56
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About GLUE

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurod...

IndustryBiotechnology
IPO DateJun 24, 2021
Employees94
Stock ExchangeNASDAQ
Ticker SymbolGLUE
Full Company Profile

Financial Performance

Financial Statements

News

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is sc...

2 weeks ago - GlobeNewsWire

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D.

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of Julli...

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its managem...

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Bu...

– Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 –

2 months ago - GlobeNewsWire

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, ...

3 months ago - GlobeNewsWire

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degrader...

Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein Translation Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein Translation

3 months ago - GlobeNewsWire

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-N...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical dat...

3 months ago - GlobeNewsWire

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be adde...

4 months ago - GlobeNewsWire

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth,...

4 months ago - GlobeNewsWire

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

– Completed upsized $255.6 million IPO; cash runway extended into late 2024

5 months ago - GlobeNewsWire

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body's ...

6 months ago - GlobeNewsWire